Diamond Therapeutics is a Toronto-based company founded in 2018. Their mission is to develop new and better drugs for mental health conditions by unlocking the promise of psychedelic compounds.
Starting with low-dose psilocybin, Diamond’s focus is on sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort—maximizing the positive impact better drugs can have on the global mental health crisis.
World-leading management, board, and advisory with decades of experience in neuroscience, pharmacology, psychiatry, drug discovery, and pre-clinical and clinical neuropsychiatric drug development.
Exclusive worldwide partnership with established Canadian pharmaceutical manufacturer Dalton Pharma Services provides Diamond with independent access to cGMP psilocybin to support clinical trials and further research.
Currently in preparation for a Phase 1 clinical trial in Canada with low-dose psilocybin. Subsequent trials will focus on social anxiety disorder, the second most prevalent form of anxiety. Existing treatments for social anxiety disorder, including SSRIs, have low treatment efficacy (<50%) and many side effects. Significant overlap in disease state characteristics offers the possibility for label claim expansion to other anxiety disorders and neuropsychiatric disorders.
Pipeline of novel chemical entities includes tryptamine analogs and small organic molecules designed to modulate neurotrophic receptor signalling and/or serotonin receptors.